Egrifta (Tesamorelin) Adult Dosing for Ages 30 to 49

Standard Dose and Administration Schedule

Tesamorelin is dosed at 2 mg subcutaneously once daily, injected into the abdomen. There is no titration schedule. The 2 mg fixed dose applies to all eligible adults regardless of body weight, BMI, or age within the approved adult population 1.

The original Egrifta formulation required two vials reconstituted and combined per dose. Theratechnologies later introduced Egrifta SV (single-vial), which simplified preparation to one vial of lyophilized tesamorelin acetate reconstituted with 0.5 mL of sterile water for injection. The SV formulation delivers the same 2 mg dose and demonstrated bioequivalence with the original product 2.

For adults aged 30 to 49, this is a period when HIV-associated lipodystrophy often becomes clinically apparent. Antiretroviral therapy (ART) regimens may have been running for a decade or longer by this stage, and the metabolic consequences of both HIV infection and chronic ART use compound during these years 3. The fixed-dose approach removes guesswork from prescribing. One vial, one injection, one site.

Patients should administer the injection at roughly the same time each day. Morning administration is commonly recommended for consistency, though no pharmacokinetic data mandate a specific time of day. If a dose is missed, patients should skip the missed dose and resume with the next scheduled injection. Doubling up is not advised 2.

How Tesamorelin Works at 2 mg

Tesamorelin is a synthetic growth hormone-releasing factor (GRF) analog. It stimulates the anterior pituitary to release endogenous growth hormone (GH), which then increases circulating insulin-like growth factor 1 (IGF-1). The downstream lipolytic effect preferentially reduces visceral adipose tissue.

The 2 mg dose was selected based on dose-ranging studies that balanced VAT reduction against the IGF-1 elevation profile. In the Phase III trial by Falutz et al. published in the New England Journal of Medicine, 412 HIV-infected adults with excess abdominal fat received tesamorelin 2 mg or placebo daily for 26 weeks. The tesamorelin group achieved a 15.2% mean reduction in trunk fat measured by CT scan, while the placebo group gained 5.0% 1. That differential of roughly 20 percentage points defined the clinical benefit threshold for the approved dose.

A subsequent 52-week extension (LIPO-010) confirmed durability of effect in patients who continued treatment, with sustained VAT reductions at one year 4. Patients who were re-randomized to placebo after the initial 26-week treatment period regained visceral fat, which underlines that tesamorelin requires continuous daily dosing to maintain results.

For adults in their 30s and 40s, this mechanism has particular relevance. GH secretion naturally declines with age at approximately 14% per decade after age 30 5. By stimulating pulsatile GH release through the physiologic GRF pathway rather than replacing GH directly, tesamorelin works within the body's existing feedback loops, avoiding the supraphysiologic GH levels associated with exogenous GH administration.

Injection Technique and Site Rotation

Proper subcutaneous technique directly affects absorption and tolerability. The abdomen is the only approved injection site. Do not inject into the arms, thighs, or buttocks.

Patients should rotate the injection site within the abdominal area, staying at least 2 inches from the navel and avoiding scar tissue, bruises, or areas of skin irritation. Using a different quadrant of the periumbilical region each day (upper left, upper right, lower left, lower right) provides a simple rotation pattern that prevents lipohypertrophy at a single site 2.

Reconstitution steps for Egrifta SV: remove the vial from refrigeration, allow it to reach room temperature (approximately 15 minutes), inject 0.5 mL of the provided sterile water diluent into the vial, roll the vial gently between the palms for 30 seconds (do not shake), and withdraw the full contents with the same syringe. The solution should appear clear and colorless. Discard it if particulate matter or discoloration is visible.

Pinch a fold of abdominal skin, insert the needle at a 90-degree angle (or 45 degrees for very lean patients), inject slowly, and hold for 5 to 10 seconds before withdrawing. Each vial and syringe is single-use 2.

Monitoring During Treatment

Baseline and periodic IGF-1 measurement is the cornerstone of tesamorelin monitoring. The FDA label recommends checking IGF-1 before starting therapy and at regular intervals during treatment 2. If IGF-1 rises persistently above the age- and sex-adjusted upper limit of normal, discontinuation should be considered.

Fasting glucose and hemoglobin A1c deserve attention as well. In Phase III data, tesamorelin was associated with a small but statistically significant increase in fasting glucose compared to placebo. Among patients with impaired glucose tolerance at baseline, this effect was more pronounced 1. For adults aged 30 to 49 who may already carry emerging insulin resistance from years of protease inhibitor-containing ART, quarterly glucose monitoring is reasonable during the first year.

The following monitoring schedule reflects both label recommendations and clinical practice patterns:

• Before starting: IGF-1, fasting glucose, HbA1c, lipid panel, CT or DEXA for VAT quantification
• At 3 months: IGF-1, fasting glucose
• At 6 months: IGF-1, fasting glucose, HbA1c, lipid panel, repeat body composition imaging to assess response
• Every 6 months thereafter: IGF-1, fasting glucose, HbA1c

A 2014 pooled analysis of the Phase III trials (N=816) showed that tesamorelin also improved triglyceride levels and the triglyceride-to-HDL ratio, secondary endpoints that matter for cardiovascular risk stratification in the 30 to 49 age group 6.

Dose Adjustments and Special Populations

There are none. The 2 mg dose is not adjusted for renal impairment, hepatic impairment, age within the adult range, or body weight. The FDA label does not include specific pharmacokinetic data in patients with renal or hepatic dysfunction, and no dose modification guidance exists for these populations 2.

For patients with diabetes or prediabetes, the dose remains 2 mg. However, closer glucose monitoring is warranted. The prescribing information notes that tesamorelin may cause glucose intolerance and recommends evaluating whether the benefits of VAT reduction outweigh the risks of worsening glycemic control in individual patients 2.

Tesamorelin is contraindicated in pregnancy (Category X). For adults aged 30 to 49, reproductive planning discussions should occur before initiation. Women of childbearing potential should use effective contraception during treatment. The drug is also contraindicated in patients with active malignancy, disruption of the hypothalamic-pituitary axis from hypophysectomy or pituitary tumor/surgery, and known hypersensitivity to tesamorelin or mannitol 2.

Efficacy Expectations at 26 and 52 Weeks

Patients should understand the timeline. Tesamorelin does not produce rapid visible changes. Clinical trial endpoints were measured at 26 weeks, and the mean trunk fat reduction of 15.2% in the Falutz et al. study, while statistically significant by CT scan, may not always translate to a dramatic change in waist circumference or appearance 1.

At 52 weeks in the LIPO-010 extension, patients who remained on tesamorelin maintained their VAT reduction, while those switched to placebo returned to baseline levels within 26 weeks 4. This finding has direct implications for patient counseling: tesamorelin is a maintenance therapy, not a course of treatment. Stopping the drug reverses the benefit.

Response varies. In the pooled Phase III analysis, approximately 64% of tesamorelin-treated patients achieved a clinically meaningful VAT reduction (defined as >8% decrease), compared to 28% of placebo-treated patients 6. For patients aged 30 to 49, higher baseline GH secretory capacity compared to older adults might contribute to a more strong response, though subgroup analyses by age decade have not been formally published.

A reasonable clinical approach: obtain baseline CT or DEXA body composition, repeat imaging at 26 weeks, and reassess whether continued therapy is justified based on the magnitude of VAT reduction and any metabolic improvements in lipids or glucose parameters.

Side Effects at the 2 mg Dose

The most common adverse reactions in Phase III trials (incidence >5% and greater than placebo) were arthralgia (13.3% vs. 11.0%), injection site erythema (8.5% vs. 2.6%), injection site pruritus (6.4% vs. 1.3%), pain in extremity (6.1% vs. 4.7%), peripheral edema (6.1% vs. 2.3%), and myalgia (5.5% vs. 2.1%) 2.

Joint pain and fluid retention reflect GH-mediated effects. These symptoms are generally mild and tend to diminish after the first 4 to 8 weeks. They are more common in patients who are GH-naive, which includes most adults in the 30 to 49 bracket who have not previously used GH-related therapies.

Injection site reactions are technique-dependent. Proper reconstitution (no shaking), allowing the solution to reach room temperature, and slow injection reduce local irritation. Hypersensitivity reactions including urticaria and pruritus have been reported rarely. Patients with known allergy to mannitol (an excipient in the formulation) should not use tesamorelin 2.

Fluid retention symptoms (peripheral edema, carpal tunnel syndrome) typically resolve without dose modification. Because tesamorelin has a fixed dose with no option for titration, management relies on symptom control (compression, elevation) rather than dose reduction. If symptoms are severe or persistent, discontinuation may be necessary 2.

Drug Interactions Relevant to Adults 30 to 49

Tesamorelin stimulates endogenous GH release, and GH affects the activity of CYP450 enzymes, particularly 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). This can alter cortisol metabolism. Patients on cortisone acetate or prednisone may need dose adjustment because GH inhibits the conversion of cortisone to active cortisol 2.

For HIV-positive adults on antiretroviral therapy, no clinically significant pharmacokinetic interactions with common ART regimens (integrase inhibitors, NRTIs, NNRTIs, or boosted protease inhibitors) have been identified in clinical trials 7. The key studies enrolled patients on stable ART, and ART modifications were not required.

The interaction with glucose-lowering medications is pharmacodynamic rather than pharmacokinetic. Since tesamorelin can raise fasting glucose, patients on metformin, sulfonylureas, or insulin may require adjustment of their antidiabetic regimen. According to the Endocrine Society's 2009 clinical practice guideline on GH deficiency in adults, glucose metabolism should be monitored closely when starting any GH-axis therapy in patients with diabetes or metabolic syndrome 8.

When to Discontinue

Stop tesamorelin if IGF-1 levels remain persistently above the upper limit of normal after retesting confirms the elevation. Discontinue if a new malignancy is diagnosed, as GH and IGF-1 signaling can promote tumor growth. Discontinue if the patient becomes pregnant 2.

Consider discontinuation if repeat imaging at 26 weeks shows no meaningful reduction in VAT, as continued therapy in non-responders exposes patients to GH-mediated risks without corresponding benefit. The 2014 pooled analysis identified that the majority of VAT reduction occurs in the first 26 weeks, with maintenance rather than continued improvement during months 7 to 12 6. If the drug has not worked by 26 weeks, it likely will not.